HSICHealthcare · Medical DistributionThe 17 Wall Street analysts covering Henry Schein, Inc. hold a median 12-month price target of $101 — +14.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 21 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Henry Schein, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Accruals (50): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HSIC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +14.1% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | BTIG | Maintains | Buy | $100 → $110 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | $86 → $100 |
| 5 Aug 2026 | BTIG | Reiterates | Buy | $100 |
| 5 Aug 2026 | Citigroup | Maintains | Buy | $100 → $112 |
| 5 Aug 2026 | UBS | Maintains | Neutral | $89 → $94 |
| 29 July 2026 | Piper Sandler | Maintains | Overweight | — |
| 29 July 2026 | Piper Sandler | Maintains | Overweight | $91 → $95 |
| 28 July 2026 | UBS | Maintains | Neutral | — |
| 28 July 2026 | UBS | Maintains | Neutral | $85 → $89 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 11 June 2026 | BTIG | Upgrade | Buy | — |
| 6 May 2026 | Mizuho | Maintains | Neutral | — |
| 6 May 2026 | UBS | Maintains | Neutral | — |
| 24 Apr 2026 | Morgan Stanley | Maintains | Underweight | — |
| 16 Apr 2026 | BTIG | Initiates | Neutral | — |
| 15 Apr 2026 | Citigroup | Initiates | Buy | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 25 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 25 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 25 Feb 2026 | JP Morgan | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HSIC appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 31% of US stocks
Cheaper than 76% of US stocks
Cheaper than 33% of US stocks
Cheaper than 26% of US stocks
Higher than 43% of US stocks
Higher than 47% of US stocks
Higher than 38% of US stocks
Higher than 56% of US stocks
Higher than 55% of US stocks
Higher than 60% of US stocks
Higher than 73% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| HSICHenry Schein, Inc. | $9.9B | 80 |
| CAHCardinal Health, Inc. | $54.5B | 96 |
| CORCencora, Inc. | $61.7B | 68 |
| MCKMcKesson Corp. | $100.6B | 86 |
| APGEApogee Therapeutics, Inc.* | $10.2B | 36 |
| BIOBio-Rad Laboratories, Inc.* | $10.2B | 92 |
| RGENRepligen Corp.* | $10.2B | 90 |
* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Henry Schein, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights Henry Schein (HSIC) as a top value stock for the long term, using its Zacks Style Scores system designed to identify strong, market-beating stocks.
Why it matters — The item frames HSIC favorably as a long-term value pick, which could draw investor attention to the company.
Zacks Investment Research examined Henry Schein's outlook, noting that its broader growth, recurring technology revenues, and savings plan support its prospects, while leverage and execution risks remain key concerns.
Why it matters — A Henry Schein watcher would care because the analysis weighs the company's growth drivers and cost-savings plan against ongoing leverage and execution risks that could affect its performance.
Henry Schein raised its 2026 outlook after reporting stronger second-quarter sales and margins. The article notes that execution of second-half cost savings remains key to sustaining earnings momentum.
Why it matters — A raised 2026 outlook signals improving sales and margin momentum, making the company's near-term savings execution a key factor for HSIC watchers to monitor.
Zacks Investment Research highlighted Henry Schein (HSIC) as a top-ranked growth stock using its Style Scores feature. The piece notes that Zacks Style Scores, part of the Zacks Premium service, help identify strong stocks for value, growth, or momentum investors.
Why it matters — HSIC watchers would care because the item signals that the company ranks highly on Zacks' growth-oriented screening criteria, drawing attention to its growth characteristics.
Zacks Investment Research highlights Henry Schein (HSIC) as a strong momentum stock, referencing its Style Scores system as a tool for identifying market-beating stocks. The piece presents HSIC favorably within the framework of momentum-based stock selection.
Why it matters — HSIC watchers would care because the piece positions Henry Schein as a notable momentum pick, potentially drawing investor attention to the stock.
The 17 Wall Street analysts covering Henry Schein, Inc. have a median 12-month price target of $101, with estimates ranging from $64 to $112. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Henry Schein, Inc., 9 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Henry Schein, Inc. 80 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Aug 2026, Henry Schein, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +14.1% from the last close, and Ticker Nerd's factor model ranks Henry Schein, Inc. 80 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Henry Schein, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HSIC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $64 to $112 over the next 12 months.
Henry Schein, Inc. returned +29.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Henry Schein, Inc. is a healthcare distribution and technology company that supplies products and services to office-based dental, medical, and veterinary professionals.
The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term". Zacks Investment Research highlights Henry Schein (HSIC) as a top value stock for the long term, using its Zacks Style Scores system designed to identify strong, market-beating stocks.
Henry Schein, Inc. is a healthcare distribution and technology company that supplies products and services to office-based dental, medical, and veterinary professionals. The company operates through global distribution, specialty products, and technology-focused segments, serving customers with consumable supplies, small equipment, laboratory products, pharmaceuticals, and practice management tools. Its portfolio also includes dental equipment, digital workflow solutions, repair services, and value-added support for clinics, laboratories, ambulatory centers, and other care settings. Henry Schein plays an important role in the healthcare supply chain by connecting manufacturers with practitioners and helping providers manage daily operations across traditional and alternate care markets. Headquartered in Melville, New York, Henry Schein focuses on essential products and services used across a broad range of healthcare practices.
CEO Mr. Frederick M. Lowery · 25,000 employees · United States · https://www.henryschein.com